Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T17:47:20.108Z.
Consensus retrieved: unavailable. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T17:47:20.108Z.
Quote observation: 2026-10-06T17:44:54.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b762030de9532cd090a02a2f6ca20f5433f7bd8b112c678bdb57b8df4aeea120
FORWARD PE RATIO
N/A
Mangoceuticals, Inc.
Market Cap
$7.11M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Mangoceuticals, Inc. (MGRX) | $7.11M | N/A |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $6.98M | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $7.04M | N/A |
| Exicure, Inc. (XCUR)vs › | $6.95M | N/A |
| KALA BIO, Inc. (KALA)vs › | $7.07M | N/A |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.07M | N/A |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.86M | N/A |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.27M | N/A |
| Skye Bioscience, Inc. (SKYE)vs › | $7.27M | N/A |
| Longeveron Inc. (LGVN)vs › | $7.27M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus fiscal-year EPS
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
